Medical Valley Academy announces press conference on innovation in the Oresund region
In Medicon Valley, EUR 300 million is spent annually on biotechnological and pharmaceutical research and development at the universities and hospitals. However, a number of recent Danish and Swedish reports have pointed out that much of the knowledge created in public sector research institutes is not being commercially utilised, despite its potential. The innovation systems in the two countries are simply not doing as well as they should.
At the end of 2003, Medicon Valley Academy appointed a strategic innovation group to provide an overall view of the strengths and weaknesses of the current innovation systems in Denmark and Sweden. The resulting analysis confirmed Medicon Valley’s weak innovation efforts compared to three other bioregions: Oxford and Stockholm in Europe, and Stanford University in Silicon Valley, USA.
The conclusion is that there is a need for a number of new measures to strengthen innovation efforts in the region. At a press conference during Biotech Forum 2004, Mikael Ørum, vice chairman of Medicon Valley Academy, presented five national and regional recommendations aimed at creating more hi-tech workplaces in Denmark and Sweden.
Read more here.
29 August 2023
Life Science Baltics 2023 | 20-21 September 2023